Here's what the filings actually reveal: the part of an mRNA medicine that's easy to talk about — the genetic sequence — is the part that's hardest to defend. The part nobody talks about — making it at scale — is the moat.
Strip away the genetic-code mystique. An mRNA sequence can be written down, emailed, and synthesized. What can't be casually copied is the industrial process of wrapping that mRNA in lipid nanoparticles, billions of doses' worth, with consistent quality every batch.
The 2021 patents land squarely on that process. Publication US20210275689A1 covers processes of preparing mRNA-loaded lipid nanoparticles — the how-to-make-it, not the what-it-is.
Stability is the other half of the manufacturing moat. US20210046192A1 covers stable compositions of mRNA-loaded lipid nanoparticles and how to make them. A dose that degrades before it reaches a patient is worthless; keeping it stable is patentable, hard-won know-how.
The crosswalk worth keeping: when evaluating an mRNA company, don't ask only what sequences it owns — ask what process and stability patents it holds. Those are the claims a competitor can't sidestep just by designing a different message.
It reframes the whole platform debate. The sequence is the headline; the manufacturing is the business. The 2021 filings show the smart money fencing off the factory floor, because that's the ground a rival actually has to cross.